Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docosahexaenoic acid (DHA) algal oil is a vegetarian-sourced omega-3 polyunsaturated fatty acid derived from marine microalgae such as *Schizochytrium* or *Crypthecodinium cohnii*. As a structural lipid, DHA is a primary component of the human brain, cerebral cortex, and retina. It functions by integrating into cellular membranes, influencing membrane fluidity, signaling pathways, and the production of specialized pro-resolving mediators (SPMs) like resolvins. It is widely used as a nutritional supplement in infant formula to support cognitive and visual development and as a dietary supplement to manage hypertriglyceridemia and support cardiovascular health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docosahexaenoic acid algal oil.